We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Probes Licenses Fluorescence Technology to LightUp

By HospiMedica staff writers
Posted on 24 Apr 2003
New DNA typing assays using fluorescence-based technology licensed from Molecular Probes (Eugene, OR, USA) are being launched by LightUp Technologies AB (Huddinge, Sweden). More...


These new assays, called LightUp Probes, can be used to identify and quantify the presence of bacteria, viruses, and other pathogens by detecting and analyzing DNA. Molecular Probes will supply advanced fluorescent stains for the assays that increase sensitivity in detecting DNA and other nucleic acids. The LightUp Probes are short peptide nucleic acid conjugates that increase in fluorescence when hybridized to target sequences. The technology is useful for identifying and quantifying targets in an extremely rapid, one-step homogenous hybridization assay. It can be used on its own or in combination with polymerase chain reaction (PCR).

"The combination of our innovative DNA typing technology and Molecular Probes' proprietary fluorescent stains is truly synergistic,” said Ulrica Sehlstedt, Ph.D., CEO of LightUp Technologies. "When enhanced with Molecular Probes' fluorescent stains, our LightUp Probes make DNA assays, including those using real-time PCR, even more sensitive, enabling their use in a wide variety of applications.”




Related Links:
Molecular Probes
LightUp Technologies

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Immobilization System
Cranial 4Pi Immobilization
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.